Associated tags: Telehealth, SIX Swiss Exchange, SHL, Health, Patient, Cardiology, ECG, Virtual Medicine, TEL, Telemedicine, Health Technology, Other Health, ISIN
Locations: US, GERMANY, BERLIN, GEORGIA, SWITZERLAND, UNITED STATES, NORTH AMERICA, MIDDLE EAST, ISRAEL, EUROPE, NEW YORK, USA
Retrieved on:
Wednesday, April 17, 2024
Cardiology,
Telemedicine,
Virtual Medicine,
General Health,
Health,
Medical Devices,
Health Technology,
Wearables,
Mobile Technology,
Technology,
USD,
Mayo Clinic,
Investment,
Telehealth,
Hand,
Doctor,
B2C,
ECG,
Imperial College London,
SHL,
Growth,
SIX Swiss Exchange In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength.
Key Points:
- In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength.
- In the US, significant advancements were made toward launching direct-to-consumer (B2C) sales of the SmartHeart® ECG platform, enhancing access to remote cardiac care.
- In the United States, SHL made significant strides in its direct-to-consumer strategy, prioritizing promotion of its SmartHeart® ECG technology.
- Erez Nachtomy, CEO of SHL, remarked: "The results from 2023 reflect our strategic approach towards stable growth and financial stability amidst the dynamic market landscape.
Technology,
Biotechnology,
Health,
Biometrics,
Apps,
Applications,
Other Health,
Telemedicine,
Virtual Medicine,
Medical Devices,
Software,
Managed Care,
Hospitals,
Health Technology,
Clinical Trials,
Cardiology,
American College,
Telehealth,
ACC,
Periodic breathing,
Dizziness,
ECG,
Imperial College London,
Patient,
Multimedia,
Chest pain,
SHL,
Photograph,
ED,
Medical imaging SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial.
Key Points:
- SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial.
- The TELE-ACS clinical trial, conducted at a large tertiary center in London, UK, from January 2022 to April 2023, involved 337 participants.
- Moreover, the study was also published in the leading Journal of the American College of Cardiology (JACC).
- These groundbreaking clinical results are an endorsement that propels us forward in our mission to redefine patient care, demonstrating the tangible benefits and efficiency of our telemedicine solutions on a global scale."
Cardiology,
Telemedicine,
Virtual Medicine,
Defense,
Military,
General Health,
Health,
Medical Devices,
Health Technology,
Mojave Desert,
Trauma,
Telehealth,
Military medicine,
SHL,
Fortification,
Nursing,
Physician,
ECG One key event during the experiment was a comprehensive multi-day army medical experiment held at Fort Irwin’s National Training Center in the Mojave Desert amidst the challenging terrains of California’s Tiefort Mountains.
Key Points:
- One key event during the experiment was a comprehensive multi-day army medical experiment held at Fort Irwin’s National Training Center in the Mojave Desert amidst the challenging terrains of California’s Tiefort Mountains.
- PC-C4, a joint, multinational experiment hosted by the U.S. Army across multiple locations in February and March allowed military medicine to explore and integrate the latest technological innovations in a field environment.
- SmartHeart’s inclusion in this prestigious experiment underscores the growing recognition of SHL’s portable ECG technology as a game-changer in the fast-paced and demanding field of military healthcare.
- It addresses a crucial need in the continuum of military medical care from initial non-battle evaluation to trauma response, to advanced interventions for intensive and continual care.
Health,
Apps,
Applications,
Technology,
Telemedicine,
Virtual Medicine,
Health Technology,
Software,
Telehealth,
SIX Swiss Exchange,
CFO SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET.
Key Points:
- SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET.
- The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO, and has been scheduled for the same day as following:
The conference call can be accessed live via the below dial-in numbers:
Retrieved on:
Thursday, February 1, 2024
Cardiology,
Biotechnology,
Technology,
Managed Care,
Other Health,
Health,
Health Technology,
Medical Devices,
Internet,
Telemedicine,
Virtual Medicine,
Clinical Trials,
Telehealth,
American College,
Clinical trial,
Patient,
Imperial College London,
SHL,
ECG,
Acute coronary syndrome,
ACC,
Pharmaceutical industry The TELE-ACS trial is a pivotal study that marks a significant milestone in telemedicine and cardiovascular care.
Key Points:
- The TELE-ACS trial is a pivotal study that marks a significant milestone in telemedicine and cardiovascular care.
- Erez Nachtomy, CEO of SHL Telemedicine, commented: “We would like to congratulate the team at Imperial College London on the acceptance of the TELE-ACS trial results for presentation at ACC 24.
- This achievement is a testament to the researchers and their rigorous effort to conduct this groundbreaking work.
- We very much look forward to seeing the presentation at ACC 24 which will share the embargoed full trial results with the global cardiology community.”
ACC 24 Participants are invited to add the session to their itinerary using the following link: https://www.abstractsonline.com/pp8/#!/10973/presentation/22832
Retrieved on:
Tuesday, December 19, 2023
Other Health,
Internet,
Professional Services,
Telemedicine,
Virtual Medicine,
Technology,
Health Technology,
Cardiology,
Insurance,
Biotechnology,
Other Technology,
Telecommunications,
Health,
Example,
SHL,
BMC,
Telehealth This event will feature the BARMER Teledoktor application, a pioneering solution developed by SHL for BARMER, exemplifying the two companies commitment to advancing telemedicine and digital health.
Key Points:
- This event will feature the BARMER Teledoktor application, a pioneering solution developed by SHL for BARMER, exemplifying the two companies commitment to advancing telemedicine and digital health.
- Erez Nachtomy, CEO of SHL Telemedicine, shared his enthusiasm: “We are incredibly excited to participate in the BMC Congress 2024, a leading forum in the healthcare industry.
- This event represents a significant opportunity for SHL Telemedicine to showcase our innovative solutions in digital healthcare, developed in collaboration with BARMER.
- We believe that our joint session will highlight the immense potential and positive impact of telemedicine on patient care.”
Retrieved on:
Monday, November 27, 2023
Cardiology,
Biotechnology,
Managed Care,
Medical Supplies,
General Health,
Health,
Medical Devices,
Other Health,
SHL,
Telehealth,
ECG,
Risk,
D2C,
Multimedia,
Heart,
Hospital,
Medical device,
Medical imaging,
Online shopping SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions is pleased to announce the soft launch of the SmartHeart® membership program in the US, marking a significant step forward in at-home healthcare.
Key Points:
- SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions is pleased to announce the soft launch of the SmartHeart® membership program in the US, marking a significant step forward in at-home healthcare.
- View the full release here: https://www.businesswire.com/news/home/20231126806466/en/
The SmartHeart® membership program is designed to revolutionize home-based access to cardiac care.
- It includes the innovative, user-friendly SmartHeart® portable 12-lead ECG device, offering round-the-clock interpretation by board-certified cardiologists and on-demand telehealth visits.
- The SmartHeart® Membership Offers to the subscribing members:
Portable 12-lead ECG device: The SmartHeart® ECG, a cutting-edge and user-friendly device, enables high-quality 12-lead ECG performance anytime and anywhere.
Health,
Medical Devices,
Technology,
Telemedicine,
Virtual Medicine,
Software,
Cardiology,
Hardware,
Direct,
American College,
ECG,
Telehealth,
Automated ECG interpretation,
Physician,
Mortality,
Cardiovascular disease,
Quality of life,
Hospital,
CIE,
SHL,
D2C,
Patient,
American College of Cardiology,
Medical imaging A keystone of clinical cardiology, the electrocardiogram (ECG) remains the most widely performed test.
Key Points:
- A keystone of clinical cardiology, the electrocardiogram (ECG) remains the most widely performed test.
- While computer-interpreted ECG programs (CIE) aid physicians in interpreting ECGs, they cannot replace the critical analysis provided by seasoned physicians.
- In establishing a US Nationwide Cardiology Network, SHL has collaborated with HeartNexus, a team of nationally recognized, board-certified cardiologists specializing in cardiac test interpretation, peer-to-peer consultations, and on-demand patient telemedicine visits.
- The ongoing developments embody SHL Telemedicine’s relentless pursuit of delivering unparalleled value to its customers and stakeholders while championing the transformative power of telemedicine.
Technology,
Medical Devices,
Clinical Trials,
Health Technology,
Telecommunications,
Telemedicine,
Virtual Medicine,
Cardiology,
Other Health,
Internet,
Health,
ECG,
Telehealth,
Clinical professor,
Imperial College London,
SHL,
Investment,
D2C,
Patient,
Mayo Clinic,
Medical device These advancements in operations infrastructure are pivotal in laying the groundwork for the upcoming D2C offerings, which the company plans to initiate in the US already this year.
Key Points:
- These advancements in operations infrastructure are pivotal in laying the groundwork for the upcoming D2C offerings, which the company plans to initiate in the US already this year.
- Erez Nachtomy, CEO of SHL Telemedicine, expressed, "Advancing towards the launch of our D2C operations in the US reflects our commitment to bridging healthcare accessibility gaps.
- The SmartHeart® technology grants remote connectivity to a network of cardiologists, ensuring regulated and compliant ECG reviews across the US.
- The ongoing developments embody SHL Telemedicine’s relentless pursuit of delivering unparalleled value to its customers and stakeholders while championing the transformative power of telemedicine.
Retrieved on:
Tuesday, September 26, 2023
Health Technology,
Telemedicine,
Virtual Medicine,
Data Management,
Other Health,
Technology,
Apps,
Applications,
Managed Care,
Biometrics,
Medical Devices,
Hospitals,
Clinical Trials,
Other Technology,
Cardiology,
Telecommunications,
Biotechnology,
Health,
SHL,
Telehealth,
Mayo Clinic,
VPM,
ECG,
Plaque,
Vulnerable plaque,
Patient,
Imperial College London,
Clinical professor,
FDA,
Pharmaceutical industry Key highlights from the presentation of the initial results include:
Key Points:
- Key highlights from the presentation of the initial results include:
A staggering decrease of- 27.5% in emergency room visits in the TELE-ACS trial1.
- Erez Nachtomy, CEO of SHL Telemedicine, commented, "The initial results from the HELP-MI and TELE-ACS trials have surpassed our expectations.
- We are extremely confident in the potential of our SmartHeart® technology, and these findings further validate its efficacy in post-MI patient care.
- We are looking forward to the continued positive impact our technology will have on telemedicine and remote patient care."
